Bella Kaufman
Overview
Explore the profile of Bella Kaufman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
8740
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perry G, Dadiani M, Kahana-Edwin S, Pavlovski A, Markus B, Hornung G, et al.
Mol Carcinog
. 2022 Sep;
61(11):1056-1070.
PMID: 36111610
Abnormal molecular processes occurring throughout the genome leave distinct somatic mutational patterns termed mutational signatures. Exploring the associations between mutational signatures and clinicopathological features can unravel potential mechanisms driving tumorigenic...
2.
Turner N, Balmana J, Poncet C, Goulioti T, Tryfonidis K, Honkoop A, et al.
Clin Cancer Res
. 2021 Jul;
27(20):5482-5491.
PMID: 34301749
Purpose: To investigate the activity of niraparib in patients with germline-mutated (gm) advanced breast cancer. Patients And Methods: BRAVO was a randomized, open-label phase III trial. Eligible patients had gm...
3.
Arun B, Han H, Kaufman B, Wildiers H, Friedlander M, Ayoub J, et al.
Eur J Cancer
. 2021 Jul;
154:35-45.
PMID: 34243076
Background: Addition of veliparib to carboplatin-paclitaxel, with continuation of veliparib monotherapy if carboplatin-paclitaxel was discontinued, improved progression-free survival (PFS) in patients with germline BRCA-associated locally advanced/metastatic HER2- breast cancer and...
4.
Puhalla S, Dieras V, Arun B, Kaufman B, Wildiers H, Han H, et al.
Clin Cancer Res
. 2021 Jun;
27(18):4983-4993.
PMID: 34131001
Purpose: Safety, efficacy, and exploratory biomarker analyses were evaluated in patients with advanced HER2-negative germline breast cancer susceptibility gene (g)-associated breast cancer enrolled in the BROCADE3 trial who received crossover...
5.
Tutt A, Garber J, Kaufman B, Viale G, Fumagalli D, Rastogi P, et al.
N Engl J Med
. 2021 Jun;
384(25):2394-2405.
PMID: 34081848
Background: Poly(adenosine diphosphate-ribose) polymerase inhibitors target cancers with defects in homologous recombination repair by synthetic lethality. New therapies are needed to reduce recurrence in patients with or germline mutation-associated early...
6.
Rugo H, Im S, Cardoso F, Cortes J, Curigliano G, Musolino A, et al.
JAMA Oncol
. 2021 Jan;
7(4):573-584.
PMID: 33480963
Importance: ERRB2 (formerly HER2)-positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but...
7.
Bernstein-Molho R, Laitman Y, Galper S, Jacobson G, Boursi B, Nili Gal-Yam E, et al.
Int J Radiat Oncol Biol Phys
. 2020 Dec;
109(5):1332-1340.
PMID: 33259931
Purpose: There is a paucity of data on the rates of ipsilateral breast tumor recurrence (IBTR) in BRCA1/2-associated breast cancer (BC). Scarcer yet are outcomes data in BRCA1/2 mutation carriers...
8.
Jacobson G, Shapira-Rotenberg T, Galper S, Gal Yam E, Zippel D, Sklair-Levy M, et al.
Plast Reconstr Surg Glob Open
. 2020 Nov;
8(5):e2822.
PMID: 33133897
No abstract available.
9.
Shenoy A, Nataraj N, Perry G, Loayza Puch F, Nagel R, Marin I, et al.
Mol Syst Biol
. 2020 Sep;
16(9):e9443.
PMID: 32960509
Tumor relapse as a consequence of chemotherapy resistance is a major clinical challenge in advanced stage breast tumors. To identify processes associated with poor clinical outcome, we took a mass...
10.
Dieras V, Han H, Kaufman B, Wildiers H, Friedlander M, Ayoub J, et al.
Lancet Oncol
. 2020 Aug;
21(10):1269-1282.
PMID: 32861273
Background: BRCA1 or BRCA2-mutated breast cancers are sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors and platinum agents owing to deficiency in homologous recombination repair of DNA damage. In this trial, we...